Baseline patient demographics and disease characteristics (ITT analysis sets)
| Low/Negative EGFR | High EGFR | |||
|---|---|---|---|---|
| <1% EGFR (n = 81) | 1- 9% EGFR (n = 111) | All patients* (N = 203) | ≥10% EGFR (N = 185) | |
| Sex, males (%) | 46 (56) | 63 (57) | 114 (56) | 100 (54) |
| Race/ethnicity, n (%) | ||||
| White/Caucasian | 59 (73) | 84 (76) | 151 (74) | 144 (78) |
| Black/African American | 15 (19) | 17 (15) | 34 (17) | 15 (8) |
| Hispanic/Latino | 3 (4) | 9 (8) | 13 (6) | 19 (10) |
| Other | 4 (5) | 1 (1) | 5 (2) | 7 (4) |
| Mean age in y (minimum, maximum) | 60 (20, 85) | 62 (35, 84) | 61 (20, 85) | 60 (27, 82) |
| Primary tumor type, n (%) | ||||
| Colon cancer | 52 (64) | 84 (76) | 145 (71) | 143 (77) |
| Rectal cancer | 29 (36) | 26 (23) | 57 (28) | 42 (23) |
| Time since primary diagnosis, median mo (minimum, maximum)† | 27.0 (10, 84) | 29.4 (7, 138) | 28.0 (7, 138) | 25.5 (7, 176) |
| Time since metastatic disease diagnosis, median mo (minimum, maximum)† | 21.1 (7, 59) | 22.1 (7, 75) | 21.9 (7, 75) | 20.6 (6, 83) |
| ECOG status, n (%) | ||||
| 0 | 39 (48) | 58 (52) | 102 (50) | 61 (33) |
| 1 | 37 (46) | 44 (40) | 87 (43) | 103 (56) |
| 2 | 5 (6) | 8 (7) | 13 (6) | 20 (11) |
| 3 | 0 | 0 | 0 | 1 (1) |
| Patients with EGFR tumor staining, n (%) | ||||
| <1% | 81 (100) | 0 | 81 (42) | 1 (1) |
| 1-9% | 0 | 111 (100) | 111 (57) | 9 (5) |
| 10-20% | 0 | 0 | 2 (1) | 116 (63) |
| 21-35% | 0 | 0 | 1 (1) | 20 (11) |
| >35% | 0 | 0 | 0 | 39 (21) |
| Tumor cells with EGFR tumor staining, mean % (SD) | 0 | 1.9 (1.7) | 1.3 (2.7) | 24.6 (20.4) |
| Highest staining intensity, n (%) | ||||
| 3+ (strong) | 0 | 3 (3) | 3 (2) | 32 (17) |
| 2+ (moderate) | 0 | 11 (10) | 11 (6) | 87 (47) |
| 1+ (weak) | 1 (1) | 97 (87) | 101 (52) | 65 (35) |
| 0 (negative) | 80 (99) | 0 | 80 (41) | 1 (1) |
| Tumor cells with highest staining intensity, mean % (SD) | 0 | 1.8 (1.5) | 1.3 (2.7) | 12.2 (11.2) |